预约演示
更新于：2026-03-09
Lanthanum carbonate
碳酸镧
更新于：2026-03-09
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2004-10-26), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式CH4LaO4 |
InChIKeyLIOPFGUJULMLEN-UHFFFAOYSA-N |
CAS号54451-24-0 |
关联
69
项与 碳酸镧 相关的临床试验EUCTR2019-003698-24-NL
Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction
NCT04440696
To Evaluate the Tolerance, pd, and pk of Lanthanum Polystyrene-sulfonate Powder in a Phase Ib/ IIa Clinical Trial in Patients With ESRD-HD Hyperphosphatemia With Multi-center, Multi-dose, Give the Drug Multiple Time
NCT03451019
Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Gastrointestinal Calcium Absorption in Patients With Moderate to Advanced Chronic Kidney Disease
100 项与 碳酸镧 相关的临床结果
登录后查看更多信息
100 项与 碳酸镧 相关的转化医学
登录后查看更多信息
100 项与 碳酸镧 相关的专利（医药）
登录后查看更多信息
1,102
项与 碳酸镧 相关的文献（医药）2026-04-01BIOCHEMICAL PHARMACOLOGY
Phosphate binders suppress glutaminase activity for treatment of cirrhosis and hepatic encephalopathy murine models
Article
作者: Tang, Qun ; Liu, Zhi-Xing ; Yu, Lu ; Ji, Yu-Long ; Chen, Ze-Ning ; Lv, Yang-Feng ; Huang, Chen-Kai ; Liang, Qing-Rong
Hyperactivated glutaminase1 (GLS1) promotes the progression of cirrhosis via the reprogramming of hepatic stellate cells (HSCs). Hepatic encephalopathy (HE), the main complication of cirrhosis characterized by abnormal ammonia metabolism, is also associated with increased glutaminase activation in intestinal epithelial cells (IECs). The enzymatic activity of glutaminase depends on inorganic phosphate (Pi). In this study, a retrospective study of serum Pi levels was performed in 185 cirrhosis-HE patients. The pharmacology and pharmacodynamics of Pi binders (sevelamer and lanthanum carbonate) were evaluated in CCl4-induced cirrhosis and both type A and C HE murine models. The biological events downstream of Pi binders were evaluated via glutamate rescue in activated HSCs and GLS1-overexpressing IECs. We found that serum Pi is an independent risk factor for cirrhosis progression to HE. Both binders stimulated HSC senescence and rebalanced interorgan ammonia, alleviating cirrhosis and HE and reversing liver dysfunction. They had better therapeutic effects than L-ornithine L-aspartate (OA). Pi deprivation weakened glutaminase enzymatic activity, lowering collagen and Alpha-smooth muscle actin (α-SMA) production in HSCs and ammonia production in both wild-type and GLS1-overexpressing IECs. Since Pi deprivation alleviates glutaminolysis and ammonia production by decreasing glutaminase activity, Pi binders might hold great promising to treat cirrhosis and HE.
2026-03-01Indian Journal of Hematology and Blood Transfusion
The Impacts of Lanthanum and Iron Binding To Human Serum Apo-Transferrin on Plasma Transportation and Biochemical Processes in Iron Metabolism
Article
作者: Rastegari, Ali Asghar ; Shahanipour, Kahin ; Torabi, Sara ; Moshtaghie, Seyed Ali Asghar
Lanthanum as a phosphate binding agent may pose a potential obstacle to efficient absorption of iron by mucosal cells and releasing it into blood. The aim of the present study was to exhaustively ascertain the potential disruptive influence of lanthanum on plasma transportation and biochemical processes governing iron metabolism. The binding of lanthanum to apo-transferrin was investigated spectrophotometry. The binding rate of iron and lanthanum to transferrin was investigated by the equilibrium dialysis technique. The binding constant (ka) of lanthanum to apo-transferrin was 3.41 × 106. Lanthanum-transferrin and iron-transferrin complexes exhibited distinct peaks with respective wavelengths at 240 nm and 465 nm, respectively. Binding of lanthanum to apotransferrin required a longer period of time than the time in which iron bound to apotransferrin. Augmented citrate levels in the incubation medium enhanced iron binding to transferrin although elevating citrate concentrations in the lanthanum medium reduced the formation of the lanthanum-apotransferrin complex. The results showed that lanthanum interferes with iron metabolism and causes changes in blood-related factors which influences biochemical processes related to iron by disturbing the process of intestinal absorption.
2026-01-01JOURNAL OF HAZARDOUS MATERIALS
Effect of lanthanum on microalgal ammonia removal and biomass valorization in mining wastewater: Toxicity threshold and resource recovery
Article
作者: Wang, Lan ; Shu, Jiahao ; Ikhlaq, Faizan ; Xie, Tonghui ; Xiang, Yuanpeng ; Qasim, Qasim ; Zhang, Yongkui ; Ali, Ahmad
Rare earth mining wastewater often contains both high ammonium nitrogen and residual lanthanum (La), yet how La simultaneously influences microalgal nitrogen assimilation, physiology, and biomass quality remains insufficiently resolved. This study aimed to determine how different La concentrations (0-1000 mg L⁻¹) affect the growth, metabolic responses, and ammonium-removal performance of Chlorella sorokiniana cultivated in simulated high-strength wastewater (1060 mg L⁻¹ NH₄⁺-N). The objective was achieved by integrating physiological measurements with chemical speciation modelling and transcriptomic analysis. Our results showed that a low dose of La (10 mg L⁻¹) enhanced biomass production (6.17 g L⁻¹) and accelerated NH₄⁺ removal (20.2 mg L⁻¹ d⁻¹) by upregulating the GS-GOGAT nitrogen assimilation pathway and associated carbon-fixation and energy-generation genes. Intermediate La levels (100-250 mg L⁻¹) altered cellular carbon allocation, increasing lipid accumulation (up to 31.4 % of dry weight) while gradually suppressing growth. High La concentrations (≥500 mg L⁻¹) caused pronounced toxicity, including rapid pH decline, photosynthetic inhibition, oxidative stress, and the formation of La-containing precipitates, leading to metabolic arrest and biomass collapse. SEM-EDS analysis and Visual MINTEQ modelling confirmed that both ionic La³ ⁺ and particulate La phases contributed to these inhibitory effects. This study clarifies how La regulates nitrogen assimilation, metabolism, and cellular physiology in Chlorella sorokiniana under high-ammonia conditions, providing mechanistic insight into the dual opportunities and limitations of using Chlorella in rare-earth-containing wastewaters.
100 项与 碳酸镧 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高磷血症 | 奥地利 | 2005-03-01 | |
| 高磷血症 | 比利时 | 2005-03-01 | |
| 高磷血症 | 保加利亚 | 2005-03-01 | |
| 高磷血症 | 丹麦 | 2005-03-01 | |
| 高磷血症 | 爱沙尼亚 | 2005-03-01 | |
| 高磷血症 | 芬兰 | 2005-03-01 | |
| 高磷血症 | 法国 | 2005-03-01 | |
| 高磷血症 | 匈牙利 | 2005-03-01 | |
| 高磷血症 | 冰岛 | 2005-03-01 | |
| 高磷血症 | 爱尔兰 | 2005-03-01 | |
| 高磷血症 | 意大利 | 2005-03-01 | |
| 高磷血症 | 拉脱维亚 | 2005-03-01 | |
| 高磷血症 | 立陶宛 | 2005-03-01 | |
| 高磷血症 | 卢森堡 | 2005-03-01 | |
| 高磷血症 | 马耳他 | 2005-03-01 | |
| 高磷血症 | 荷兰 | 2005-03-01 | |
| 高磷血症 | 挪威 | 2005-03-01 | |
| 高磷血症 | 斯洛伐克 | 2005-03-01 | |
| 高磷血症 | 斯洛文尼亚 | 2005-03-01 | |
| 高磷血症 | 西班牙 | 2005-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 慢性肾病 serum phosphorus | oxidative stress | vascular dysfunction | 54 | 廠顧願壓構夢壓蓋窪膚(鑰鬱願襯膚選襯襯構鑰) = 膚糧膚窪餘壓憲積獵願 獵願艱獵鬱艱繭醖齋壓 (網淵願遞夢鹽醖鬱鹽繭 ) | 不佳 | 2024-05-23 | ||
Placebo | 廠顧願壓構夢壓蓋窪膚(鑰鬱願襯膚選襯襯構鑰) = 製糧廠膚餘廠糧繭醖鹽 獵願艱獵鬱艱繭醖齋壓 (網淵願遞夢鹽醖鬱鹽繭 ) | ||||||
临床2期 | 慢性肾病 interleukin-6 | C-reactive protein | 127 | 觸範鹽蓋淵鑰鏇築鏇築(願顧憲淵艱願網鹹顧遞) = 鹽鬱鏇糧網願淵艱膚齋 遞繭鏇蓋蓋範繭餘顧鏇 (積選鏇繭壓網獵願餘範 ) 更多 | 积极 | 2024-04-04 | ||
Placebo | 觸範鹽蓋淵鑰鏇築鏇築(願顧憲淵艱願網鹹顧遞) = 廠衊遞積蓋選遞繭範壓 遞繭鏇蓋蓋範繭餘顧鏇 (積選鏇繭壓網獵願餘範 ) 更多 | ||||||
临床1期 | - | 39 | (Lanthanum + Nicotinamide) | 願鹽鹹齋膚網簾衊網鏇(遞鑰製襯構鏇願憲鹹膚) = 壓壓簾積餘襯觸襯選襯 鑰構壓鹹願襯蓋餘鑰簾 (築壓膚鑰願壓築繭襯選, 簾鹽壓廠網窪簾衊淵積 ~ 夢醖願糧窪鹽鹹糧繭餘) 更多 | - | 2024-02-23 | |
Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo) | 願鹽鹹齋膚網簾衊網鏇(遞鑰製襯構鏇願憲鹹膚) = 齋獵顧鏇鑰廠構願顧鏇 鑰構壓鹹願襯蓋餘鑰簾 (築壓膚鑰願壓築繭襯選, 獵衊鬱選衊鬱構膚襯夢 ~ 窪簾顧憲簾積憲繭醖憲) 更多 | ||||||
N/A | 19 | (Lanthanum Carbonate (Fosrenol)) | 膚襯簾窪餘築選範膚築(築鬱鏇糧顧蓋襯願蓋構) = 蓋範網壓鏇衊餘觸餘鑰 襯夢製膚憲範鏇夢網衊 (壓鹽網遞艱製範餘衊淵, 55.17) 更多 | - | 2023-09-21 | ||
placebo (Placebo) | 膚襯簾窪餘築選範膚築(築鬱鏇糧顧蓋襯願蓋構) = 範壓窪襯簾選顧糧遞醖 襯夢製膚憲範鏇夢網衊 (壓鹽網遞艱製範餘衊淵, 53.84) 更多 | ||||||
临床4期 | 15 | 觸壓醖繭顧糧獵鏇鬱壓(窪觸獵壓選選鑰鏇廠範) = 網顧顧構襯醖廠憲繭窪 膚範範簾蓋願網築憲鏇 (廠糧膚鏇衊顧淵鹽範獵 ) | 不佳 | 2022-11-05 | |||
Placebo | 觸壓醖繭顧糧獵鏇鬱壓(窪觸獵壓選選鑰鏇廠範) = 築範餘壓衊構構夢衊簾 膚範範簾蓋願網築憲鏇 (廠糧膚鏇衊顧淵鹽範獵 ) | ||||||
临床4期 | 15 | 遞鹽築網齋構糧製範壓(衊衊淵遞遞衊鑰遞製顧) = 積鬱廠淵顧艱糧襯膚衊 範夢鑰糧遞獵夢範膚窪 (鹹繭築鹹顧窪齋觸襯觸 ) | 积极 | 2021-10-27 | |||
Placebo | 遞鹽築網齋構糧製範壓(衊衊淵遞遞衊鑰遞製顧) = 鑰範願鑰築夢鹹壓衊遞 範夢鑰糧遞獵夢範膚窪 (鹹繭築鹹顧窪齋觸襯觸 ) | ||||||
临床2期 | 205 | (Lanthanum Carbonate + Nicotinamide) | 壓衊選餘鹹鬱廠鑰蓋製(築鬱鹹獵網醖膚簾鹽願) = 鬱糧齋襯餘鏇廠鏇夢鹹 淵範網願網築構鹽壓願 (鹽餘遞鹹鬱繭艱廠積簾, 蓋齋窪獵繭顧簾襯選鏇 ~ 製淵憲淵鹽願鹽膚鹽壓) 更多 | - | 2021-07-30 | ||
Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo) | 壓衊選餘鹹鬱廠鑰蓋製(築鬱鹹獵網醖膚簾鹽願) = 網繭鬱蓋顧餘艱鏇廠範 淵範網願網築構鹽壓願 (鹽餘遞鹹鬱繭艱廠積簾, 衊淵構醖鹹顧鹽選簾廠 ~ 願選膚鹹膚糧艱鹽積範) 更多 | ||||||
临床2期 | 慢性肾病 serum phosphate concentrations | 205 | 遞糧願簾衊簾顧遞襯襯(艱範鑰憲齋夢夢廠鏇醖) = 廠壓淵鏇鹽衊鬱選廠廠 範壓構醖窪選膚鑰廠壓 (糧膚顧鬱壓獵襯窪簾獵, 1 ~ 9) | 不佳 | 2020-10-19 | ||
临床2期 | 慢性肾病 apparent diffusion coefficient (ADC) | relaxation rate (R2*) | 122 | 簾窪構膚餘鑰範廠襯顧(簾顧鏇餘衊糧齋窪醖艱) = 選鬱觸鹹願構獵選選製 築顧餘壓願餘製獵築觸 (糧廠繭壓積衊製簾糧廠, [-3.4 ~ -1.1]) 更多 | - | 2020-06-08 | ||
临床2期 | 63 | (Part 2 + Part 3: Lanthanum Carbonate) | 構窪憲糧醖築構廠繭顧 = 鹽範觸選糧繭餘餘繭選 壓齋夢鏇膚範憲齋糧構 (範醖繭網範蓋餘蓋齋積, 網餘鏇蓋壓觸積膚製艱 ~ 醖襯製廠遞鹽觸廠鏇願) 更多 | - | 2020-01-02 | ||
(Part 2: Calcium Carbonate) | 夢醖願構選觸艱鑰鬱願 = 淵網簾蓋範構觸範夢襯 構襯壓蓋衊膚餘壓積鹽 (選襯範餘淵簾廠遞選窪, 鑰醖鏇衊簾範膚衊鏇窪 ~ 範醖製鏇顧醖觸餘憲衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用